Evolutionary Genomics Stock Today
| FNAM Stock | USD 0.0002 0.00 0.00% |
PerformanceWeakest
| Odds Of DistressSmall
|
Evolutionary Genomics is selling at 2.0E-4 as of the 25th of December 2025; that is No Change since the beginning of the trading day. The stock's lowest day price was 2.0E-4. Evolutionary Genomics has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of June 2025 and ending today, the 25th of December 2025. Click here to learn more.
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. The company has 6.66 M outstanding shares. More on Evolutionary Genomics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Evolutionary Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Evolutionary Genomics [FNAM] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.66 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evolutionary Genomics's market, we take the total number of its shares issued and multiply it by Evolutionary Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Evolutionary Genomics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 6.66 M outstanding shares.
Evolutionary Genomics currently holds about 897.78 K in cash with (1.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Evolutionary Genomics Probability Of Bankruptcy
Ownership AllocationEvolutionary Genomics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Evolutionary Ownership Details
Evolutionary Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Evolutionary Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Other Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.